BD (Becton, Dickinson and Company) announced on January 13, 2025, that its BD Onclarity™ HPV Assay has been officially added to the American Society for Colposcopy and Cervical Pathology (ASCCP) Enduring Risk-Based Management Guidelines. This inclusion is due to the assay's ability to individually identify more high-risk types of HPV.
The new guidelines represent an advancement in cervical cancer prevention and management, offering a more precise approach to HPV screening that improves treatment design. The BD Onclarity™ HPV Assay employs extended genotyping, identifying six of the 14 cancer-causing HPV types individually and grouping the remaining seven into three pooled results.
This detailed analysis allows for more precise risk assessment, persistence-tracking, and personalized treatment plans. The guidelines also support the use of self-collection methods for cervical cancer screening, which is offered with the BD Onclarity™ HPV assay in healthcare settings, improving access for individuals facing barriers to traditional screening.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.